- Report
- September 2026
- 199 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 198 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 193 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- January 2026
- 191 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 188 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- September 2026
- 192 Pages
Global
From €3340EUR$3,545USD£2,781GBP
€3711EUR$3,939USD£3,090GBP
- Report
- January 2026
- 280 Pages
Global
From €3403EUR$3,613USD£2,834GBP
€4004EUR$4,250USD£3,334GBP
- Report
- July 2026
- 120 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- June 2026
- 143 Pages
Global
From €3768EUR$3,999USD£3,137GBP
- Report
- May 2026
- 143 Pages
Global
From €3768EUR$3,999USD£3,137GBP
- Report
- April 2026
- 141 Pages
Global
From €3768EUR$3,999USD£3,137GBP
- Report
- April 2026
- 147 Pages
Global
From €3768EUR$3,999USD£3,137GBP
- Report
- April 2026
- 145 Pages
Global
From €3768EUR$3,999USD£3,137GBP
- Report
- February 2026
- 143 Pages
Global
From €3768EUR$3,999USD£3,137GBP
- Report
- December 2025
- 150 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- October 2026
- 150 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- September 2026
- 120 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- June 2026
- 150 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- May 2026
- 120 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- May 2026
- 150 Pages
Global
From €5606EUR$5,950USD£4,667GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more